Skip to main content

Table 2 Breakdown of costs (€) by health state.

From: Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis

Cost components per cycle (6-months) NESRD ESRD First 2 cycles ESRD Subsequent cycles Terminal ESRD
moxonidine 0.3 mg/d 82.80 - - -
nitrendipine 20 mg/d 74.40 - - -
Other antihypertensives 93.90 - - -
Consultations, diagnostics, laboratory services, diuretics 213.00 - - -
Dialysis including consultations, drugs, diagnostics and laboratory services* - 34,522.00 32,627.00 -
Transplantation including consultations, drugs, diagnostics and laboratory services* - 22,850.00 4,570.00 -
Terminal ESRD care - - - 1,416.00
  1. † z-index: Cost of antihypertensives based on patient usage: 89% on ACE I (ddd enalapril 25 mg) and 11% on ARB (ddd losartan 50 mg), and 35.6% on beta blocker (ddd atenolol 75 mg) and 27.4% on alpha blocker (ddd doxazosin 4 mg). Costs of diuretics were assumed to be included in NESRD costs based on manuscript van Hout et al.
  2. ‡ van Hout et al
  3. * de Wit et al